Andrew Obenshain Appointed as CEO of Inventiva

Inventiva, a biopharmaceutical company focused on treatments for metabolic dysfunction-associated steatohepatitis (MASH), has announced Andrew Obenshain as its new Chief Executive Officer. Obenshain, joining the Board of Directors, succeeds co-founder Frédéric Cren, who steps down after leading the company since its inception in 2012.

This leadership transition aligns with Inventiva’s strategic focus on preparing for potential commercialization in the U.S. market, which is pivotal for MASH. With upcoming Phase 3 data, Obenshain's expertise in drug approvals and organizational growth is expected to bolster Inventiva’s position in the MASH sector. Under Cren's leadership, the company evolved into a recognized leader in MASH therapy development.

Obenshain's prior role as CEO of bluebird bio and his extensive background in drug development are seen as assets for Inventiva's future pursuits in global commercialization.